<i>EGFR</i> Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan - Concepedia

Concepedia

Publication | Closed Access

<i>EGFR</i> Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

218

Citations

31

References

2008

Year

Toshimi Takano, Tomoya Fukui, Yuichiro Ohe, Koji Tsuta, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Koh Furuta,

Journal of Clinical Oncology

Abstract

EGFR mutations significantly predict both a survival benefit from gefitinib and a favorable prognosis in patients with advanced lung adenocarcinoma.

References

	Year	Citations

Page 1